{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:10:50Z","timestamp":1791461450236,"version":"4.3.4"},"reference-count":95,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"vor","delay-in-days":366,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.bbadis.2014.11.022","type":"journal-article","created":{"date-parts":[[2014,12,6]],"date-time":"2014-12-06T22:10:25Z","timestamp":1417903825000},"page":"651-657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Myasthenia gravis and related disorders: Pathology and molecular pathogenesis"],"prefix":"10.1016","volume":"1852","author":[{"given":"James C.","family":"Ha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Richman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2014.11.022_bb0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0404.2006.00606.x","article-title":"Clinical aspects of neuromuscular transmission disorders","volume":"183","author":"Evoli","year":"2006","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0010","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/01.phm.0000171169.79816.4c","article-title":"Advances in the diagnosis of neuromuscular junction disorders","volume":"84","author":"Meriggioli","year":"2005","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2006.00605.x","article-title":"Immunology of disorders of neuromuscular transmission","volume":"183","author":"Vincent","year":"2006","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0020","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-2004-830900","article-title":"Lambert\u2013Eaton myasthenic syndrome","volume":"24","author":"Mareska","year":"2004","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0035-3787(04)70888-7","article-title":"Lambert\u2013Eaton myasthenic syndrome","volume":"160","author":"Newsom-Davis","year":"2004","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0030","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S0035-3787(04)71010-3","article-title":"Neuromyotonia","volume":"160","author":"Newsom-Davis","year":"2004","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0035","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.coph.2004.12.007","article-title":"Current understanding of congenital myasthenic syndromes","volume":"5","author":"Engel","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0040","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/mus.20440","article-title":"Molecular architecture of the neuromuscular junction","volume":"33","author":"Hughes","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0045","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/neu.10137","article-title":"Building the vertebrate neuromuscular synapse","volume":"53","author":"Burden","year":"2002","journal-title":"J. Neurobiol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0050","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.conb.2005.12.003","article-title":"Assembly of the postsynaptic membrane at the neuromuscular junction: paradigm lost","volume":"16","author":"Kummer","year":"2006","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0055","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/35097557","article-title":"Induction, assembly, maturation and maintenance of a postsynaptic apparatus","volume":"2","author":"Sanes","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0060","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/1531-8249(200004)47:4<504::AID-ANA14>3.0.CO;2-Q","article-title":"IgG from \u201cseronegative\u201d myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor","volume":"47","author":"Blaes","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0065","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0960-8966(96)00009-0","article-title":"Clinical heterogeneity of seronegative myasthenia gravis","volume":"6","author":"Evoli","year":"1996","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0070","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0075","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1212\/01.WNL.0000041625.41937.FF","article-title":"AChR phosphorylation and indirect inhibition of AChR function in seronegative MG","volume":"59","author":"Plested","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0080","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nn0703-653","article-title":"Agrin\/MuSK signaling: willing and Abl","volume":"6","author":"Burden","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0085","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0166-2236(03)00131-0","article-title":"Molecular dissection of neuromuscular junction formation","volume":"26","author":"Hoch","year":"2003","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0090","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0095","doi-asserted-by":"crossref","first-page":"e36603","DOI":"10.1371\/journal.pone.0036603","article-title":"Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population","volume":"7","author":"Maniaol","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0100","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1468-1331.2008.02242.x","article-title":"Paraneoplastic myasthenia gravis: immunological and clinical aspects","volume":"15","author":"Skeie","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0105","doi-asserted-by":"crossref","first-page":"7270","DOI":"10.1158\/1078-0432.CCR-04-0735","article-title":"Autoantibody profiles and neurological correlations of thymoma","volume":"10","author":"Vernino","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0110","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/icvts\/ivt510","article-title":"Is thymectomy in non-thymomatous myasthenia gravis of any benefit?","volume":"18","author":"Diaz","year":"2014","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0115","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1126\/science.180.4088.871","article-title":"Autoimmune response to acetylcholine receptor","volume":"180","author":"Patrick","year":"1973","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0120","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1084\/jem.141.6.1365","article-title":"Experimental autoimmune myasthenia: a model of myasthenia gravis in rats and guinea pigs","volume":"141","author":"Lennon","year":"1975","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0125","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/clim.1999.4807","article-title":"Animal models of myasthenia gravis","volume":"94","author":"Christadoss","year":"2000","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0130","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ana.410160502","article-title":"Myasthenia gravis and myasthenic syndromes","volume":"16","author":"Engel","year":"1984","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0135","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<453::AID-MUS3>3.0.CO;2-O","article-title":"Acetylcholine receptors and myasthenia","volume":"23","author":"Lindstrom","year":"2000","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0140","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.4049\/jimmunol.138.10.3269","article-title":"Refractoriness to a second episode of experimental myasthenia gravis. Correlation with AChR concentration and morphologic appearance of the postsynaptic membrane","volume":"138","author":"Corey","year":"1987","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0145","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1073\/pnas.77.2.755","article-title":"Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits","volume":"77","author":"Tzartos","year":"1980","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0150","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"Rodgaard","year":"1987","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0155","first-page":"257","article-title":"Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles","volume":"49","author":"Vincent","year":"1982","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0160","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1073\/pnas.80.13.4089","article-title":"Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia","volume":"80","author":"Gomez","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0165","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0170","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1126\/science.850793","article-title":"Myasthenic immunoglobulin accelerates acetylcholine receptor degradation","volume":"196","author":"Kao","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0175","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1212\/WNL.41.9.1497","article-title":"Inflammation at the neuromuscular junction in myasthenia gravis","volume":"41","author":"Maselli","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0180","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1212\/WNL.43.6.1167","article-title":"Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients","volume":"43","author":"Nakano","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0185","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1749-6632.1998.tb10962.x","article-title":"Antibody effector mechanisms in myasthenia gravis. The complement hypothesis","volume":"841","author":"Richman","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0190","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1212\/WNL.38.4.514","article-title":"Seronegative myasthenia gravis","volume":"38","author":"Soliven","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0195","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ana.410300407","article-title":"Seronegative myasthenia gravis: a plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM","volume":"30","author":"Yamamoto","year":"1991","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0200","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0205","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","article-title":"Clinical aspects of MuSK antibody positive seronegative MG","volume":"60","author":"Sanders","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0210","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1474-4422(03)00306-5","article-title":"Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets","volume":"2","author":"Vincent","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0215","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.20069","article-title":"Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients","volume":"30","author":"Zhou","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0220","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1212\/01.WNL.0000150587.71497.B6","article-title":"Thymus changes in anti-MuSK-positive and -negative myasthenia gravis","volume":"64","author":"Lauriola","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0225","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG","volume":"57","author":"Leite","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0230","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0235","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1432-1327.1998.2530382.x","article-title":"Tyrosine phosphorylation of the muscle-specific kinase is exclusively induced by acetylcholine receptor-aggregating agrin fragments","volume":"253","author":"Hopf","year":"1998","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0240","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1073\/pnas.90.7.2895","article-title":"Muscle-specific trk-related receptor with a kringle domain defines a distinct class of receptor tyrosine kinases","volume":"90","author":"Jennings","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0245","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0896-6273(95)90146-9","article-title":"Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury","volume":"15","author":"Valenzuela","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0250","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0166-2236(96)10066-7","article-title":"Genes at the junction\u2014candidates for congenital myasthenic syndromes","volume":"20","author":"Vincent","year":"1997","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0255","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neuroscience.2006.03.035","article-title":"The tetratricopeptide repeat domains of rapsyn bind directly to cytoplasmic sequences of the muscle-specific kinase","volume":"141","author":"Antolik","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1432-1327.1999.00765.x","article-title":"Formation of the neuromuscular junction. Agrin and its unusual receptors","volume":"265","author":"Hoch","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0265","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/bies.20305","article-title":"The synaptic muscle-specific kinase (MuSK) complex: new partners, new functions","volume":"27","author":"Strochlic","year":"2005","journal-title":"Bioessays"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0270","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0275","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ana.21371","article-title":"Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction","volume":"63","author":"Cole","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0280","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jneuroim.2006.03.016","article-title":"Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK)","volume":"175","author":"Jha","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0285","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/archneurol.2011.2200","article-title":"Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes","volume":"69","author":"Richman","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0290","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1172\/JCI21545","article-title":"Induction of myasthenia by immunization against muscle-specific kinase","volume":"116","author":"Shigemoto","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0295","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.molimm.2011.04.024","article-title":"Complement activation by (auto-) antibodies","volume":"48","author":"Daha","year":"2011","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0300","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"van der Neut Kolfschoten","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0305","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1242\/dev.02696","article-title":"LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction","volume":"133","author":"Weatherbee","year":"2006","journal-title":"Development"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0310","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2008.10.002","article-title":"Lrp4 is a receptor for Agrin and forms a complex with MuSK","volume":"135","author":"Kim","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0315","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.neuron.2008.10.006","article-title":"LRP4 serves as a coreceptor of agrin","volume":"60","author":"Zhang","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0320","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0325","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0330","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0140-6736(53)91358-0","article-title":"Bronchial neoplasm with myasthenia; prolonged apnoea after administration of succinylcholine","volume":"265","author":"Anderson","year":"1953","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0335","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/jama.1957.02970480021005","article-title":"Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors","volume":"163","author":"Eaton","year":"1957","journal-title":"J. Am. Med. Assoc."},{"issue":"Pt 3","key":"10.1016\/j.bbadis.2014.11.022_bb0340","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/brain\/111.3.577","article-title":"The Lambert\u2013Eaton myasthenic syndrome. A review of 50 cases","volume":"111","author":"O'Neill","year":"1988","journal-title":"Brain"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0345","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","article-title":"Calcium-channel antibodies in the Lambert\u2013Eaton syndrome and other paraneoplastic syndromes","volume":"332","author":"Lennon","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0350","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/jnnp.58.1.85","article-title":"An improved diagnostic assay for Lambert\u2013Eaton myasthenic syndrome","volume":"58","author":"Motomura","year":"1995","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0355","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/mus.20332","article-title":"Lambert\u2013Eaton myasthenic syndrome has a more progressive course in patients with lung cancer","volume":"32","author":"Wirtz","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0360","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00415-003-1063-7","article-title":"The epidemiology of myasthenia gravis, Lambert\u2013Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland","volume":"250","author":"Wirtz","year":"2003","journal-title":"J. Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0365","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","article-title":"Lambert\u2013Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies","volume":"10","author":"Titulaer","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0370","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jneuroim.2004.10.018","article-title":"HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert\u2013Eaton myasthenic syndrome","volume":"159","author":"Wirtz","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0375","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/awf178","article-title":"Phenotypic variants of autoimmune peripheral nerve hyperexcitability","volume":"125","author":"Hart","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0380","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/WCO.0b013e32833cc968","article-title":"Autoimmune mediated neuromuscular junction defects","volume":"23","author":"Farrugia","year":"2010","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0385","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.bbagen.2007.10.001","article-title":"Antibodies against gangliosides and ganglioside complexes in Guillain\u2013Barre syndrome: new aspects of research","volume":"1780","author":"Kusunoki","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0390","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1085-9489.2005.0010202.x","article-title":"The immunobiology of Guillain\u2013Barre syndromes","volume":"10","author":"Willison","year":"2005","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0395","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1152\/physrev.2000.80.2.717","article-title":"Neurotoxins affecting neuroexocytosis","volume":"80","author":"Schiavo","year":"2000","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0400","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0968-0004(02)02177-1","article-title":"Botulinum and tetanus neurotoxins: structure, function and therapeutic utility","volume":"27","author":"Turton","year":"2002","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0405","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1083\/jcb.103.2.535","article-title":"Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis","volume":"103","author":"Black","year":"1986","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0410","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1002\/j.1460-2075.1993.tb06171.x","article-title":"Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1\/syntaxin","volume":"12","author":"Blasi","year":"1993","journal-title":"EMBO J."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0415","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0014-5793(93)80448-4","article-title":"Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds","volume":"335","author":"Schiavo","year":"1993","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0420","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1124\/mol.54.2.407","article-title":"Inhibition of neuronal calcium channels by a novel peptide spider toxin, DW13.3","volume":"54","author":"Sutton","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0425","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/15563650902832608","article-title":"Electrophysiological correlates of intermediate syndrome following acute organophosphate poisoning","volume":"47","author":"Jayawardane","year":"2009","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0430","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0006-3002(59)90320-8","article-title":"Chemical nature of the DFP-binding site of pseudocholinesterase","volume":"34","author":"Jansz","year":"1959","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0435","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.410010403","article-title":"A new myasthenic syndrome with end-plate acetylcholinesterase deficiency, small nerve terminals, and reduced acetylcholine release","volume":"1","author":"Engel","year":"1977","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0440","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/ana.410390607","article-title":"A beta-subunit mutation in the acetylcholine receptor channel gate causes severe slow-channel syndrome","volume":"39","author":"Gomez","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0445","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1749-6632.2012.06803.x","article-title":"New horizons for congenital myasthenic syndromes","volume":"1275","author":"Engel","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0450","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1212\/WNL.57.2.279","article-title":"Presynaptic congenital myasthenic syndrome due to quantal release deficiency","volume":"57","author":"Maselli","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.11.022_bb0455","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ana.410110603","article-title":"A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel","volume":"11","author":"Engel","year":"1982","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0460","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/ana.410400521","article-title":"End-plate acetylcholine receptor deficiency due to nonsense mutations in the epsilon subunit","volume":"40","author":"Engel","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0465","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1196\/annals.1254.015","article-title":"Mechanistic diversity underlying fast channel congenital myasthenic syndromes","volume":"998","author":"Sine","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0470","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11910-002-0057-7","article-title":"Congenital myasthenic syndromes: genetic defects of the neuromuscular junction","volume":"2","author":"Ohno","year":"2002","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.bbadis.2014.11.022_bb0475","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1749-6632.1993.tb22930.x","article-title":"Congenital myasthenic syndrome associated with paucity of synaptic vesicles and reduced quantal release","volume":"681","author":"Walls","year":"1993","journal-title":"Ann. N. Y. Acad. Sci."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443914003640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443914003640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T13:50:18Z","timestamp":1690725018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443914003640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":95,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0925443914003640"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2014.11.022","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myasthenia gravis and related disorders: Pathology and molecular pathogenesis","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2014.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}